Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Anifrolumab Coverage Update | OpenPay…
    Ask Trek AI about this page
    CurrentHealthSpringPolicy RX501.138

    Anifrolumab-fnia

    Customize your policy alerts

    Sign up for healthspring Policy RX501.138 alerts

    Get alerted when Policy RX501.138 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of anifrolumab-fnia under HealthSpring medical policy, including general medical-policy requirements and a specific Ohio exception for certain off-label uses of FDA-approved drugs.

    Policy Summary
    PayerHealthSpring
    PolicyAnifrolumab-fnia
    Policy CodePolicy RX501.138
    Change TypeNo material change
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming moderate-to-severe active SLE, documented autoantibodies, current non-biologic standard-of-care treatment, and no concurrent SLE biologic therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    AdultsEligible patient population
    Moderate to severe SLECovered disease severity
    At least 1Concurrent non-biologic standard-of-care treatment
    Not coveredSevere active CNS lupus or lupus nephritis
    J0491Listed HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    OHOhio exception

    Coverage Criteria

    Initial Therapy for Active Systemic Lupus Erythematosus

    Anifrolumab-fnia (Saphnelo) may be considered medically necessary for initial therapy when ALL of the following criteria are met:

    ALL of the following

    • Patient is an adult with a diagnosis of moderate to severe systemic lupus erythematosus (SLE), without severe active central nervous system lupus or severe active lupus nephritis.
    • Laboratory testing has documented the presence of autoantibodies, such as antinuclear antibodies, anti-double-stranded DNA, anti-Smith (Anti-Sm), anti-Sjögren's-syndrome-related antigen A, or anti-Sjögren's-syndrome-related antigen B.
    • Patient is currently receiving at least one standard-of-care treatment for active SLE, such as antimalarials, corticosteroids, or immunosuppressants, that is not a biologic.
    • Patient is not receiving anifrolumab-fnia (Saphnelo) in combination with other biologics used to treat SLE, such as belimumab or rituximab.

    Medically Necessary Use

    Anifrolumab-fnia (Saphnelo) may be considered medically necessary for the treatment of active systemic lupus erythematosus when ALL of the following criteria are met:

    ALL of the following

    • Patient is an adult with a diagnosis of moderate to severe systemic lupus erythematosus (SLE), without severe active central nervous system lupus or severe active lupus nephritis.
    • Laboratory testing has documented the presence of autoantibodies, such as antinuclear antibodies, anti-double-stranded DNA, anti-Smith (Anti-Sm), anti-Sjögren's-syndrome-related antigen A, or anti-Sjögren's-syndrome-related antigen B.
    • Patient is currently receiving at least one standard-of-care treatment for active SLE, such as antimalarials, corticosteroids, or immunosuppressants, that is not a biologic.
    • Patient is not receiving anifrolumab-fnia (Saphnelo) in combination with other biologics used to treat SLE, such as belimumab or rituximab.

    Experimental, Investigational, or Unproven Use

    Anifrolumab-fnia (Saphnelo) is considered experimental, investigational, and/or unproven when used for ANY of the following:

    ANY of the following

    • Any indication not approved by the U.S. Food and Drug Administration (FDA), including all other non-FDA-approved indications.

    Carefully check state regulations and/or the member contract. Coverage is never required when the FDA has recognized a use as contraindicated, and coverage is not required for non-formulary drugs. For members residing in Ohio, state law may require coverage of an FDA-approved drug prescribed for a use recognized as safe and effective in specified standard medical reference compendia or supported by qualifying medical literature, even when the use is not FDA-approved. Medical literature support requires confirmation of safety and efficacy in two articles from major peer-reviewed professional medical journals; evidence limited to case studies or case series is insufficient.

    Coverage does not include anifrolumab-fnia for patients with severe active central nervous system lupus or severe active lupus nephritis.

    Anifrolumab-fnia must not be used concurrently with other biologics used to treat systemic lupus erythematosus, including belimumab or rituximab.

    The medically necessary criteria exclude patients with severe active central nervous system lupus or severe active lupus nephritis.

    The medically necessary criteria exclude concurrent use of anifrolumab-fnia with other biologics used to treat systemic lupus erythematosus, including belimumab or rituximab.

    Anifrolumab-fnia (Saphnelo) is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Anifrolumab-fnia (Saphnelo) is considered experimental, investigational, and/or unproven for all indications not approved by the FDA.

    Initial Therapy

    Initial Therapy

    Initial coverage requires all of the following:

    Initial anifrolumab-fnia eligibility

    • Diagnosis and disease severity: Moderate to severe systemic lupus erythematosus is documented, without severe active central nervous system lupus or severe active lupus nephritis.
    • Autoantibodies: Laboratory testing documents the presence of relevant autoantibodies.

      Examples include antinuclear antibodies, anti-double-stranded DNA, anti-Smith, anti-Sjögren's-syndrome-related antigen A, or anti-Sjögren's-syndrome-related antigen B antibodies.

    • Standard-of-care therapy: The patient is currently receiving at least one non-biologic standard-of-care treatment for active systemic lupus erythematosus.At least 1 treatment

    Billing and Coding

    CPT CodesCPT
    No codes listed
    HCPCS CodesHCPCS
    J0491

    Authorization and Documentation Requirements

    Prior Authorization

    Medical-Necessity Authorization Required

    Submit a prior authorization request establishing that an adult has active systemic lupus erythematosus (SLE) that is moderate to severe and meets all applicable medical-necessity requirements. The request must also document the required exclusions and treatment conditions.

    Documentation Required

    Clinical Criteria for Authorization

    For authorization, document moderate-to-severe active SLE, qualifying autoantibody laboratory evidence, current standard-of-care treatment that is not a biologic, and absence of severe active central nervous system lupus or severe active lupus nephritis. Also confirm that Saphnelo is not being administered with another biologic used to treat SLE.

    Documentation Required

    Ohio Off-Label Evidence Requirements

    Clinical Background

    Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system attacks the body's own tissues. This can cause widespread inflammation and tissue damage involving organs such as the joints, skin, brain, lungs, kidneys, and blood vessels. Anifrolumab is used with standard therapy for adults with moderate to severe SLE, particularly when skin and joint involvement is present; it has not been evaluated or recommended for severe active lupus nephritis or severe active central nervous system lupus.

    Definitions and Clinical Terms

    Systemic lupus erythematosus (SLE)
    NatureAn autoimmune disease in which the immune system attacks its own tissue.
    EffectsCauses widespread inflammation and tissue damage in affected organs, including the joints, skin, brain, lungs, kidneys, and blood vessels.
    SymptomsMay include fatigue, skin rashes, fevers, and pain or swelling in the joints; other manifestations include sun sensitivity, oral ulcers, arthritis, organ problems, seizures, psychosis, and blood-cell or immunological abnormalities.
    Anifrolumab
    Drug classType I interferon receptor antagonist.
    MechanismBlocks the activity of type I interferons, including interferon-alpha, interferon-beta, and interferon-kappa.

    Administration Setting

    Billing Rule

    Schedule intravenous infusion every 4 weeks

    Administer Saphnelo by intravenous infusion every 4 weeks, consistent with the administration schedule used in the clinical studies.

    Policy Summary
    PayerHealthSpring
    PolicyAnifrolumab-fnia
    Policy CodePolicy RX501.138
    Change TypeNo material change
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming moderate-to-severe active SLE, documented autoantibodies, current non-biologic standard-of-care treatment, and no concurrent SLE biologic therapy.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyBilling and CodingAuthorization and Documentation RequirementsClinical BackgroundDefinitions and Clinical TermsAdministration Setting

    Examples include antimalarials, corticosteroids, or immunosuppressants.

  1. Biologic combination restriction: Saphnelo is not used in combination with another biologic used to treat SLE.

    Examples include belimumab or rituximab.

  2. Initial Therapy

    Initial therapy may be considered medically necessary when ALL of the following are met:

    Initial anifrolumab-fnia criteria: The patient is an adult with moderate-to-severe active systemic lupus erythematosus; does not have severe active central nervous system lupus or severe active lupus nephritis; has laboratory documentation of autoantibodies; is currently receiving at least one non-biologic standard-of-care therapy for active systemic lupus erythematosus; and is not receiving Saphnelo in combination with another biologic used to treat SLE.All criteria required

    Examples of standard-of-care treatment include antimalarials, corticosteroids, or immunosuppressants. Examples of prohibited concurrent biologics include belimumab and rituximab.

    For members residing in Ohio, coverage of an FDA-approved drug for an off-label use may be required when the use is recognized as safe and effective in an adopted standard medical reference compendium or supported by medical literature. Submit evidence from two articles in major peer-reviewed professional medical journals supporting the proposed use as generally safe and effective; case studies or case series alone are insufficient.

    • Examples of accepted journals include the Journal of the American Medical Association, New England Journal of Medicine, and Lancet.
    • Accepted evidence may include randomized, double-blind, placebo-controlled clinical trials.
    Documentation Required

    Clinical Eligibility Documentation

    Include documentation of the SLE diagnosis and severity, qualifying autoantibody results, current standard-of-care therapy, and all required exclusions before requesting Saphnelo authorization.

    • Standard-of-care treatment may include an antimalarial, corticosteroid, or immunosuppressant.
    • The standard-of-care treatment must not be a biologic.
    Documentation Required

    Required Clinical Documentation

    The clinical record and authorization submission must establish adult moderate-to-severe active SLE and address every applicable coverage requirement, including disease manifestations, laboratory evidence, current therapy, and biologic-treatment exclusions.

    • Document that severe active central nervous system lupus and severe active lupus nephritis are absent.
    • Document that Saphnelo is not being used with another biologic for SLE.
    Documentation Required

    Autoantibody Laboratory Evidence

    Submit laboratory testing documenting the presence of qualifying SLE autoantibodies as part of the authorization request.

    • Antinuclear antibodies.
    • Anti-double-stranded DNA antibodies.
    • Anti-Smith (Anti-Sm) antibodies.
    • Anti-Sjögren's-syndrome-related antigen A (anti-SSA) antibodies.
    • Anti-Sjögren's-syndrome-related antigen B (anti-SSB) antibodies.
    Denial Risk

    Contraindicated or Non-Formulary Use

    Coverage is never required when the FDA has recognized the use as contraindicated, and coverage is not required for non-formulary drugs. Verify the member contract and applicable state requirements before submitting or adjudicating the request.

    Denial Risk

    Non-FDA-Approved Indication

    Saphnelo is considered experimental, investigational, and/or unproven for all indications that are not FDA-approved, subject to applicable state law and member-contract requirements.

    Denial Risk

    Severe CNS Lupus or Lupus Nephritis

    Do not authorize Saphnelo for severe active central nervous system lupus or severe active lupus nephritis under these criteria. The submitted documentation must establish that these manifestations are absent.

    Denial Risk

    Combination With Another SLE Biologic

    Do not authorize Saphnelo when it is administered in combination with another biologic used to treat SLE.

    • Examples include belimumab and rituximab.
    Denial Risk

    Non-FDA-Approved Indications

    All non-FDA-approved indications for anifrolumab-fnia (Saphnelo) are considered experimental, investigational, and/or unproven under this policy.

    Denial Risk

    Severe Active CNS Lupus or Lupus Nephritis

    Coverage is not supported for Saphnelo in severe active central nervous system lupus or severe active lupus nephritis. These conditions must be excluded from the clinical documentation.

    Denial Risk

    No Combination With Another SLE Biologic

    Do not use Saphnelo with another biologic used to treat SLE because combination therapy does not meet the policy criteria.

    • Examples include belimumab and rituximab.
    Clinical contextUsed with standard therapy for adults with moderate to severe SLE without severe active lupus nephritis or neuropsychiatric SLE; benefit may be particularly relevant for skin and joint involvement.
    BICLA
    Full nameBritish Isles Lupus Assessment Group based Composite Lupus Assessment.
    Organ-domain responseRequires improvement in all organ domains with moderate or severe activity at baseline, including reduction of baseline BILAG A scores to B/C/D and baseline BILAG B scores to C/D.
    No disease worseningRequires no BILAG worsening in other organ systems, no worsening from baseline in SLEDAI-2K, and no worsening in lupus disease activity on the Physician's Global Assessment.
    Treatment requirementsRequires no treatment discontinuation and no use of restricted medication beyond the protocol-allowed threshold.
    SRI-4
    Full nameSystemic Lupus Erythematosus Responder Index-4.
    SLEDAI-2K thresholdAt Week 52, requires a reduction from baseline of at least 4 points in SLEDAI-2K.
    New organ involvementRequires no new organ system affected, defined as 1 or more BILAG A or 2 or more BILAG B items compared with baseline.
    Disease activityRequires no worsening from baseline in lupus disease activity, defined as an increase of at least 0.30 points on the 3-point Physician's Global Assessment visual analogue scale.
    Treatment requirementsRequires no treatment discontinuation and no use of restricted medication beyond the protocol-allowed threshold.
    Moderate-to-severe active SLE
    DefinitionClinically active systemic lupus erythematosus classified as moderate to severe in an adult patient.
    Clinical-trial severity contextPivotal studies enrolled adults with SLEDAI-2K scores of at least 6 points, organ-level involvement based on BILAG assessment, and a Physician's Global Assessment score of at least 1 despite standard SLE therapy.
    Excluded manifestationsSevere active central nervous system lupus, including neuropsychiatric SLE, and severe active lupus nephritis are excluded.
    Autoantibodies
    PurposeLaboratory evidence that supports an SLE diagnosis in the appropriate clinical context.
    Antinuclear antibodiesAntinuclear antibodies (ANA) are among the laboratory tests supporting SLE classification and diagnosis.
    SLE-specific antibodiesAnti-double-stranded DNA (anti-dsDNA) and anti-Smith (Anti-Sm) antibodies support the criteria for an SLE diagnosis and are highly predictive in patients with relevant clinical features.
    Additional antibodiesAnti-Sjögren's-syndrome-related antigen A and anti-Sjögren's-syndrome-related antigen B antibodies may also occur in patients with lupus, although they are less specific for SLE.